Related Experiment Video

Updated: Jun 16, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Treatment of HBV/HCV coinfection

Andrej Potthoff1, Michael P Manns, Heiner Wedemeyer

  • 1Hannover Medical School, Medizinische Hochschule Hannover, Department of Gastroenterology, Hepatology and Endocrinology, Carl Neuberg Str. 1, D-30625 Hannover, Germany.

Expert Opinion on Pharmacotherapy
|February 20, 2010
PubMed

Insights

Hepatitis B (HBV) and Hepatitis C (HCV) coinfection increases liver disease risk. Treatment requires detailed evaluation, with PEG-IFN plus ribavirin often preferred for dominant HCV, but monitoring for HBV rebound is crucial.

Area of Science:

  • Hepatology
  • Virology
  • Infectious Diseases

Background:

  • Hepatitis B (HBV) and Hepatitis C (HCV) are leading causes of chronic liver disease globally.
  • HBV/HCV coinfection affects millions, significantly raising risks for cirrhosis, hepatocellular carcinoma (HCC), and mortality.
  • Understanding coinfection is vital due to complex viral interactions and potential for fluctuating dominance.

Purpose of the Study:

  • To review the epidemiology of HBV/HCV coinfection.
  • To explore viral interactions and clinical features of coinfection.
  • To summarize current and emerging treatment options for HBV/HCV coinfected patients.

Main Methods:

  • Review of existing literature on HBV/HCV coinfection.
  • Analysis of virological dominance patterns and their implications.
  • Evaluation of treatment strategies, including combination therapies.

Main Results:

  • HBV/HCV coinfection presents complex pathophysiological interactions.
  • Treatment individualization is key, with specific antiviral agents indicated based on viral load and dominance.
  • Pegylated interferon (PEG-IFN) plus ribavirin is a primary option for dominant HCV replication.

Conclusions:

  • Thorough serological and virological assessment is mandatory before initiating antiviral therapy in coinfected patients.
  • While PEG-IFN plus ribavirin is recommended for dominant HCV, careful monitoring for HBV rebound post-HCV treatment is essential.
  • Close surveillance of both HBV and HCV is necessary throughout and after treatment to manage potential viral flares.
Abstract

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...